

**ANNOUNCEMENTS IN CONJUNCTION WITH  
THERATECHNOLOGIES ANNUAL MEETING**

**Montreal, Canada – May 24, 2013**—Theratechnologies Inc. (TSX: TH) today held its annual meeting of shareholders, chaired by Paul Pommier, chairman of the board of Theratechnologies.

At the meeting, the following people were elected as company directors by a majority of the votes.

	FOR	% FOR	ABSENTION	% ABSTENTION
Gilles Cloutier	16,493,771	93.63	1,122,061	6.37
Gérald A. Lacoste	15,977,261	90.70	1,638,571	9.30
Dawn Svoronos	17,138,172	97.29	477,660	2.71
Jean-Denis Talon	16,492,371	93.62	1,123,461	6.38
Luc Tanguay	17,018,571	96.61	597,261	3.39
Paul Pommier	16,488,369	93.60	1,127,463	6.40

At the meeting, the shareholder rights plan was renewed, and KPMG was appointed as auditors of the Corporation.

**Appointment of new chairman**

Immediately after the meeting, the board members met to appoint Dawn Svoronos as the new chair of the board, as previously announced.

They also confirmed Luc Tanguay as president and CEO of Theratechnologies.

**About Theratechnologies**

Theratechnologies (TSX: TH) is a biopharmaceutical company that specializes in innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor peptides. Further information about Theratechnologies is available on the Company's website at [www.theratech.com](http://www.theratech.com), on SEDAR at [www.sedar.com](http://www.sedar.com) and on the Securities and Exchange Commission website at [www.sec.gov](http://www.sec.gov).

**Information:**

Denis Boucher  
NATIONAL Public Relations  
514-843-2393